A homozygous TARS2 variant is a novel cause of syndromic neonatal diabetes.
No Thumbnail Available
All Authors
Donis, R.
Patel, KA.
Wakeling, MN.
Johnson, MB.
Amoli, MM.
Yildiz, M.
Akcay, T.
Aspi, I.
Yong, J.
Yaghootkar, H.
LTHT Author
Yong, James
LTHT Department
Leeds Children's Hospital
Children & Young People's Diabetes
Children & Young People's Diabetes
Non Medic
Publication Date
2025
Item Type
Journal Article
Language
Subject
Subject Headings
Abstract
AIMS: Neonatal diabetes is a monogenic condition which can be the presenting feature of complex syndromes. The aim of this study was to identify novel genetic causes of neonatal diabetes with neurological features including developmental delay and epilepsy.
METHODS: We performed genome sequencing in 27 individuals with neonatal diabetes plus epilepsy and/or developmental delay of unknown genetic cause. Replication studies were performed in 123 individuals with diabetes diagnosed aged <=1 year without a known genetic cause using targeted next-generation sequencing.
RESULTS: Three individuals, all diagnosed with diabetes in the first week of life, shared a rare homozygous missense variant, p.(Arg327Gln), in TARS2. Replication studies identified the same homozygous variant in a fourth individual diagnosed with diabetes at 1 year. One proband had epilepsy, one had development delay and two had both. Biallelic TARS2 variants cause a mitochondrial encephalopathy (COXPD-21) characterised by severe hypotonia, epilepsy and developmental delay. Diabetes is not a known feature of COXPD-21. Current evidence suggests that the p.(Arg327Gln) variant disrupts TARS2's regulation of the mTORC1 pathway which is essential for beta-cells.
CONCLUSIONS: Our findings establish the homozygous p.(Arg327Gln) TARS2 variant as a novel cause of syndromic neonatal diabetes and uncover a role for TARS2 in pancreatic beta-cells.
Journal
Diabetic Medicine